Leap Therapeutics Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
36
- Stock Symbol
-
LPTX
- Investments
-
4
- Share Price
-
$0.34
- (As of Tuesday Closing)
Leap Therapeutics General Information
Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205.
Contact Information
Website
www.leaptx.com
Formerly Known As
HealthCare Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 47 Thorndike Street
- Suite B1-1
- Cambridge, MA 02141
- United States
+1 (617) 000-0000
Leap Therapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.34 | $0.35 | $0.33 - $1.95 | $33.3M | 99M | 779K | -$0.48 |
Leap Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (2,875) | 161,704 | 76,903 | 18,254 |
| Revenue | 375 | 1,500 | 1,500 | 0 |
| EBITDA | (53,644) | (40,550) | (27,536) | (33,146) |
| Net Income | (53,282) | (40,587) | (27,514) | (32,900) |
| Total Assets | 82,165 | 117,911 | 54,371 | 7,448 |
| Total Debt | 774 | 469 | 552 | 1,026 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Leap Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Leap Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Leap Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer b
Biotechnology
Cambridge, MA
36
As of 2021
00000
000000 - 000
00000
000000
or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariat
000000000000000
Mountain View, CA
000
As of 0000
00000
0.00
0000-00-00
000000&0
00000
000000
na aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris ni
0000000000000
Tubingen, Germany
000
As of 0000
00000
000000000
00000
Add Comparison
Leap Therapeutics Competitors (42)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Chemocentryx | Formerly VC-backed | Mountain View, CA | 000 | 00000 | 000000&0 | 00000 |
| 00000000 | Formerly VC-backed | Tubingen, Germany | 000 | 00000 | 000000000 | 00000 |
| 0000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000000 000 | Corporation | New York, NY | 000 | 00000 | 0000000000 | 00000 |
Leap Therapeutics Patents
Leap Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020386091-A1 | Methods of treating cancer using dkk-1-inhibitors | Pending | 22-Nov-2019 | 000000000 | |
| CA-3158661-A1 | Methods of treating cancer using dkk-1-inhibitors | Pending | 22-Nov-2019 | 000000000 | |
| EP-4061419-A1 | Methods of treating cancer using dkk-1-inhibitors | Pending | 22-Nov-2019 | 000000000 | |
| EP-4031175-A1 | Use of dkk-1 inhibitors for treating cancer | Pending | 19-Sep-2019 | 000000000000 | |
| US-20220381786-A1 | Use of dkk-1 inhibitors for treating cancer | Pending | 19-Sep-2019 | G01N33/57484 |
Leap Therapeutics Executive Team (8)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Douglas Onsi JD | Chief Executive Officer, President & Board Member | ||
| Augustine Lawlor | Chief Operating Officer, Operations | ||
| Christine Granfield | Executive & Vice President | ||
| Mark O'Mahony | Chief Manufacturing Officer | ||
| Jason Baum Ph.D | Vice President & Head of Translational Medicine |
Leap Therapeutics Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Mirabelli Ph.D | Leap Therapeutics | Chairman & Board Member | 000 0000 |
| Douglas Onsi JD | Leap Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 |
| James Cavanaugh Ph.D | HealthCare Ventures | Board Member | 000 0000 |
| Joseph Loscalzo Ph.D | Leap Therapeutics | Board Member | 000 0000 |
| Nissim Mashiach | MacroCure | Board Member | 000 0000 |
Leap Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Leap Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Leap Therapeutics Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 17-Jan-2023 | 0000000000 | Drug Discovery | 0000000 0 | |
| 000000000 | 23-Jan-2017 | 0000000000 | Biotechnology | 000000000 | |
| 0000 | 21-Jan-2016 | 000000 00 | Drug Discovery | 0000000 0 | |
| HealthCare Pharmaceuticals | 21-Jan-2016 | Merger of Equals | Biotechnology |
Leap Therapeutics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000 00000000000 | Drug Discovery | New Hope, PA | 0000 |
Leap Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
